{
  "cik": 1625297,
  "cik_padded": "0001625297",
  "entityName": "Indivior Pharmaceuticals, Inc.",
  "fiscal_years": [
    {
      "accn": "0001628280-26-012237",
      "filed": "2026-02-26",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "buybacks": "USD",
        "capex": "USD",
        "cash": "USD",
        "cost_of_revenue": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "gross_profit": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "buybacks": 11000000.0,
        "capex": 66000000.0,
        "cash": 195000000.0,
        "cost_of_revenue": 245000000.0,
        "eps_diluted": 1.64,
        "free_cash_flow": -93000000.0,
        "gross_profit": 994000000.0,
        "net_income": 210000000.0,
        "operating_cash_flow": -27000000.0,
        "operating_income": 262000000.0,
        "revenue": 1239000000.0,
        "stockholders_equity": -98000000.0,
        "total_assets": 1201000000.0,
        "total_liabilities": 1300000000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "gross_margin": "ratio",
        "net_margin": "ratio",
        "operating_margin": "ratio",
        "revenue_growth_yoy": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "gross_margin": 0.8022598870056498,
        "net_margin": 0.16949152542372878,
        "operating_margin": 0.21146085552865213,
        "revenue_growth_yoy": 0.04292929292929293,
        "roa_avg2y": 0.16686531585220502,
        "roa_period_end": 0.17485428809325562,
        "roe_avg2y": -0.9655172413793104
      }
    },
    {
      "accn": "0001628280-26-012237",
      "filed": "2026-02-26",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "buybacks": "USD",
        "capex": "USD",
        "cash": "USD",
        "cost_of_revenue": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "gross_profit": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "buybacks": 173000000.0,
        "capex": 29000000.0,
        "cash": 319000000.0,
        "cost_of_revenue": 231000000.0,
        "eps_diluted": 0.05,
        "free_cash_flow": 7000000.0,
        "gross_profit": 957000000.0,
        "net_income": 7000000.0,
        "operating_cash_flow": 36000000.0,
        "operating_income": 38000000.0,
        "revenue": 1188000000.0,
        "stockholders_equity": -337000000.0,
        "total_assets": 1316000000.0,
        "total_liabilities": 1652000000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "gross_margin": "ratio",
        "net_margin": "ratio",
        "operating_margin": "ratio",
        "revenue_growth_yoy": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "gross_margin": 0.8055555555555556,
        "net_margin": 0.005892255892255892,
        "operating_margin": 0.03198653198653199,
        "revenue_growth_yoy": 0.08691674290942361,
        "roa_avg2y": 0.004554326610279766,
        "roa_period_end": 0.005319148936170213,
        "roe_avg2y": -0.026871401151631478
      }
    },
    {
      "accn": "0001628280-26-012237",
      "filed": "2026-02-26",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "buybacks": "USD",
        "capex": "USD",
        "cash": "USD",
        "cost_of_revenue": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "gross_profit": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "buybacks": 33000000.0,
        "capex": 8000000.0,
        "cash": 316000000.0,
        "cost_of_revenue": 174000000.0,
        "eps_diluted": -0.92,
        "free_cash_flow": -308000000.0,
        "gross_profit": 919000000.0,
        "net_income": -126000000.0,
        "operating_cash_flow": -300000000.0,
        "operating_income": -152000000.0,
        "revenue": 1093000000.0,
        "stockholders_equity": -184000000.0,
        "total_assets": 1758000000.0,
        "total_liabilities": 1942000000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "gross_margin": "ratio",
        "net_margin": "ratio",
        "operating_margin": "ratio",
        "revenue_growth_yoy": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "gross_margin": 0.8408051235132662,
        "net_margin": -0.11527904849039342,
        "operating_margin": -0.13906678865507777,
        "revenue_growth_yoy": 0.21309655937846836,
        "roa_period_end": -0.07167235494880546,
        "roe_avg2y": 1.2663316582914572
      }
    },
    {
      "accn": "0001628280-26-012237",
      "filed": "2026-02-26",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "buybacks": "USD",
        "capex": "USD",
        "cost_of_revenue": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "gross_profit": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "buybacks": 90000000.0,
        "capex": 5000000.0,
        "cost_of_revenue": 152000000.0,
        "eps_diluted": -0.32,
        "free_cash_flow": -9000000.0,
        "gross_profit": 749000000.0,
        "net_income": -44000000.0,
        "operating_cash_flow": -4000000.0,
        "operating_income": -81000000.0,
        "revenue": 901000000.0,
        "stockholders_equity": -15000000.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "gross_margin": "ratio",
        "net_margin": "ratio",
        "operating_margin": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "gross_margin": 0.8312985571587126,
        "net_margin": -0.048834628190899,
        "operating_margin": -0.08990011098779133,
        "roe_avg2y": -0.8301886792452831
      }
    },
    {
      "accn": "0001625297-25-000016",
      "filed": "2025-03-03",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": 121000000.0
      },
      "period_end": "2021-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001628280-26-012237",
    "filed": "2026-02-26",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001625297.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001625297.json"
  },
  "ticker": "INDV"
}